Physician profile
Joel Goode
NPI 1649247198
$4,783.48
in general payments reported to CMS, 2019-2025
43 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $170 · 2021: $305 · 2022: $942 · 2023: $1,547 · 2024: $708 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,888.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $887.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $502.77 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.49 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $312.92 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $306.12 | 2022-2025 | |
| Depuy Synthes Sales INC. | $234.46 | 2020-2023 | Inhance |
| Supernus Pharmaceuticals, INC. | $217.34 | 2023-2024 | Qelbree, Qelbree |
| Astrazeneca Pharmaceuticals Lp | $169.37 | 2019-2025 | Airsupra, Breztri |
| Abbott Laboratories | $165.43 | 2021-2023 | Proclaim, Freestyle Libre 3 |
| Corium, LLC | $157.75 | 2022-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $135.97 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $129.99 | 2019-2024 | Jardiance, Emgality, Zepbound |
| Janssen Pharmaceuticals, INC | $89.60 | 2022-2024 | Spravato |
| Amarin Pharma, INC. | $85.78 | 2019-2022 | |
| Shire North American Group INC | $74.64 | 2019 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Goode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.